Press & News

Apr 10, 2024 and Infervision Partner on AI Solution to Aid in Earlier Detection and Clinical Workup of Lung Cancer

New partnership to identify and quantify lung nodules

SAN FRANCISCO – April 10, 2024 –, the leader in AI-powered disease detection and intelligent care coordination, today announced a partnership with Infervision, an AI medical technology company. The partnership will incorporate InferRead Lung CT.AI, Infervision’s FDA-cleared AI solution for lung nodule detection, into the ecosystem.

Nationally, only 25.8% of lung cancer cases are diagnosed at an early stage when the five-year survival rate is much higher (61%). Unfortunately, 44% of cases are not caught until a late stage when the survival rate is only 7%. Lung cancer screening with annual low-dose CT scans for those at high risk can reduce the lung cancer death rate by up to 20%.1 Delays in diagnosis and appropriate treatment increase the risk of advanced-stage lung disease and higher mortality rates.

“With the advancement of artificial intelligence (‘AI’) technology, early detection of lung cancer can be improved significantly,” said Steve Sweeny, Vice President, Business Development and Strategy at “We are excited to collaborate with Infervision, harnessing the power of AI to gain insights from CT scans. This partnership will improve the standard of care for these lung cancer patients and help healthcare providers and radiologists coordinate care for improved patient outcomes.”

The InferRead Lung CT.AI automated solution identifies lung nodules and efficiently performs detailed nodule quantifications. Infervision’s capability is a complement to’s growing care coordination platform, which will introduce InferRead Lung CT.AI into clinicians’ daily workflow – providing detailed analytical information to assist with optimal decision-making and treatment to improve patient care.

“We are pleased to be working with to advance the identification of lung nodules and to have the opportunity to incorporate into the ecosystem of over 1,600 hospitals across the US,” said Matt Deng, Vice President, Head of Infervision America. “With the integration of both medical AI solutions, we aim to assist the physician with accurate disease diagnosis and detailed analytical information for optimal decision-making and treatment choices.”


About is the pioneer in the use of AI algorithms and machine learning to increase the speed of diagnosis and care across 1,500+ hospitals and health systems in the U.S. and Europe. The AI-powered OneTM is an intelligent care coordination solution that identifies more patients with a suspected disease, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes. Backed by real-world clinical evidence, One delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information visit